$PRLD News

Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension

Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M

D. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8

Prelude Therapeutics shares are trading higher after the company announced the presentation of new preclinical data from its lead development candidate, PRT13722. The company price a $90 million offering of 18 million shares at $4.44 per share.

Prelude Therapeutics shares are trading higher after the company announced the presentation of new preclinical data from its lead development candidate, PRT13722. The company price a $90 million offering of 18 million shares at $4.44 per share.

Prelude Therapeutics Prices $90M Offering of 18M Shares At $4.44 Per Share

Prelude Therapeutics Announces Presentation Of New Preclinical Data From PRT13722 For The Treatment Of Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Breast Cancer, And Believes That PRT13722 Is A Highly Differentiated, First-In-Class, Orally Bioavailable, Potent And Highly-selective Kat6A Degrader

Prelude Therapeutics Announces Poster With Preclinical Data On Its Oral KAT6A Selective Degrader Accepted For Presentation At American Association For Cancer Research Annual Meeting 2026

Citizens Maintains Market Outperform on Prelude Therapeutics, Raises Price Target to $6

Prelude Therapeutics shares are trading higher. The company reported Q4 financial results.

Prelude Therapeutics Earnings Report: Q4 Overview

Prelude Therapeutics Q4 EPS $(0.20) Misses $(0.03) Estimate, Sales $5.640M Miss $35.000M Estimate

Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO

Prelude Therapeutics shares are trading higher after the company announced the FDA clearance to proceed with a Phase 1 study under its IND for PRT12396, a mutant-selective JAK2V617F inhibitor.

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

Prelude Therapeutics Gets FDA Clearance Of Investigational New Drug Application For PRT12396

Prelude Therapeutics Files For Resale From Time To Time Of Up To 6.3M Shares Of Voting Common Stock By Selling Stockholder

Reported Saturday, Prelude Therapeutics Presents ASH 2025 Data Highlighting PRT12396 JAK2V617F-Selective JH2 Inhibitor And mCALR-Targeted CDK9 Degrader Antibody Conjugate In MPNs

Prelude Therapeutics Inc (PRLD) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ...